# US 2024/0189242 A1 · Lipid nanoparticle compositions and methods of formulating the same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0189242 A1
- Document ID: US20240189242A1
- Status: Published application
- Kind: A1
- Application number: 18/277,346
- Filed: 2022-02-18
- Published: 2024-06-13
- Earliest claimed: 2021-02-19
- Assignees: ModernaTX, Inc.
- Applicants: Modernatx, Inc.
- Inventors: Meredith PACKER; Dipendra GYAWALI; Serenus HUA; Gabor BUTORA; Gregory John MERCER
- Web page: https://patentgrep.com/patent/US20240189242A1

## CPC

- A61K 31/7105: Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
- A61K 9/1617: {Organic compounds, e.g. phospholipids, fats}
- A61K 9/1641: {obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers}
- A61K 9/5123: {Organic compounds, e.g. fats, sugars}
- A61K 47/18: Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- C12N 15/88: using microencapsulation, e.g. using {amphiphile} liposome vesicle
- A61K 48/0041: {the non-active part being polymeric}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Provided herein are methods of reducing adduct formation in lipid nanoparticle compositions comprising a polynucleotide, such as mRNA, and an ionizable lipid; also disclosed are lipid nanoparticle compositions having a reduced adduct content, and methods of detecting the adducts.

## Claims

### Claim 1

A composition comprising a lipid nanoparticle comprising a polynucleotide and an ionizable lipid, wherein the ionizable lipid comprises a tertiary amine group and can decompose into a secondary amine and/or a reactive aldehyde species capable of interacting with the polynucleotide to form an ionizable lipid-polynucleotide adduct impurity, wherein less than about 10% of the polynucleotide is in the form of an ionizable lipid-polynucleotide adduct impurity.

### Claim 2 (depends on 1)

A composition according to claim 1, wherein the polynucleotide is mRNA.

### Claim 3 (depends on 1, 2)

A composition according to claim 1 or claim 2, wherein the lipid nanoparticle further comprises a phospholipid, a cholesterol, and a PEG-lipid.

### Claim 4 (depends on 1, 2, 3)

A composition according to any one of claims 1-3, wherein less than about 5% of the polynucleotide is in the form of an ionizable lipid-polynucleotide adduct impurity.

### Claim 5 (depends on 1, 2, 3, 4)

A composition according to any one of claims 1-4, wherein less than about 1% of the polynucleotide is in the form of an ionizable lipid-polynucleotide adduct impurity.

### Claim 6 (depends on 1, 2, 3, 4, 5)

A composition according to any one of claims 1-5, wherein the ionizable lipid is selected from:

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

A composition according to any one of claims 1-6, wherein an amount of the ionizable lipid-polynucleotide adduct impurity increases at an average rate of less than about 2% per day when stored at a temperature at about 25° C. or below, or increases at an average rate of less than about 0.5% per day when stored at a temperature at about 5° C. or below, or increases at an average rate of less than about 0.5% per day when stored at a refrigerated temperature, optionally wherein the refrigerated temperature is about 5° C.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

A composition according to of any one of claims 1-7, further comprising a buffer selected from sodium phosphate, sodium citrate, sodium succinate, histidine, histidine-HCl, sodium malate, sodium carbonate, and TRIS (tris(hydroxymethyl)aminomethane).

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

A composition according to of any one of claims 1-8, further comprising a cryoprotectant, optionally wherein the cryoprotectant is selected from mannitol, sucrose, trehalose, lactose, glycerol, dextrose, and combinations thereof.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

A composition according to any one of claims 1-9, wherein the ionizable lipid-polynucleotide adduct impurity comprises an aldehyde-polynucleotide adduct impurity.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

A composition according to any one of claims 1-10, wherein an amount of lipid aldehydes in the composition is less than about 50 ppm.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

A method for preparing a lipid nanoparticle composition according to any one of claims 1-11, comprising combining the ionizable lipid and the polynucleotide to provide the lipid nanoparticle composition, and then treating the composition to reduce formation of ionizable lipid-polynucleotide adduct.

### Claim 13

A method of inhibiting formation of one or both of N-oxides and aldehydes in a composition comprising an ionizable lipid and a polynucleotide, wherein the ionizable lipid comprises a tertiary amine group and can decompose into a secondary amine and/or a reactive aldehyde species capable of interacting with the polynucleotide to form an ionizable lipid-polynucleotide adduct impurity, wherein the method comprises treating the composition to reduce formation of ionizable lipid-polynucleotide adduct, wherein less than about 10% of the polynucleotide is in the form of ionizable lipid-polynucleotide adduct impurity.

### Claim 14 (depends on 12, 13)

A method according to claim 12 or claim 13, wherein the treating comprises one or more of:
treating the composition with a reducing agent;
treating the composition with a chelating agent;
adjusting the pH of the composition;
adjusting the temperature of the composition; and
adjusting the buffer in the composition.

### Claim 15 (depends on 12, 13, 14)

A method according to any one of claims 12-14, further comprising performing one or more of the following steps before combining the ionizable lipid and the polynucleotide:
treating the ionizable lipid with a scavenging agent;
treating the ionizable lipid with a reductive treatment agent;
treating the ionizable lipid with a reducing agent;
treating the ionizable lipid with a chelating agent;
treating the polynucleotide with a reducing agent; and
treating the polynucleotide with a chelating agent.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

A method for preparing a lipid nanoparticle composition according to any one of claims 1-11, comprising:
performing one or more of the following steps before combining the ionizable lipid and the polynucleotide:
treating the ionizable lipid with a scavenging agent;
treating the ionizable lipid with a reductive treatment agent;
treating the ionizable lipid with a reducing agent;
treating the ionizable lipid with a chelating agent;
treating the polynucleotide with a reducing agent; and
treating the polynucleotide with a chelating agent;
and then combining the ionizable lipid with the polynucleotide.

### Claim 17 (depends on 12, 13, 14, 15, 16)

A method according to any one of claims 12-16, wherein the composition comprises a reduced amount of ionizable lipid-polynucleotide adduct impurity as compared to a control composition, wherein in the control composition neither the first nor second preparation nor the composition has been treated with a reducing agent or a chelating agent.

### Claim 18 (depends on 15, 16)

A method according to any one of claims 15-16, wherein the scavenging agent comprises one or more selected from (O-(2,3,4,5,6-Pentafluorobenzyl)hydroxylamine hydrochloride) (PFBHA), methoxyamine (e.g., methoxyamine hydrochloride), benzyloxyamine (e.g., benzyloxyamine hydrochloride), ethoxyamine (e.g., ethoxyamine hydrochloride), 4-[2-(aminooxy)ethyl]morpholine dihydrochloride, butoxyamine (e.g., tert-butoxyamine hydrochloride), 4-Dimethylaminopyridine (DMAP), 1,4-diazabicyclo[2.2.2]octane (DABCO), Triethylamine (TEA), Piperidine 4-carboxylate (BPPC), and combinations thereof.

### Claim 19 (depends on 15, 16)

A method according to any one of claims 15-16, wherein the reductive treatment agent comprises a boron compound, optionally wherein the boron compound is selected from sodium borohydride and bis(pinacolato)diboron).

### Claim 20 (depends on 14, 15, 16)

A method according to any one of claims 14-16, wherein the chelating agent comprises immobilized iminodiacetic acid.

### Claim 21 (depends on 14, 15, 16)

A method according to any one of claims 14-16, wherein the reducing agent comprises an immobilized reducing agent, optionally wherein the immobilized reducing agent is selected from immobilized diphenylphosphine on silica (Si-DPP), immobilized thiol on agarose (Ag-Thiol), immobilized cysteine on silica (Si-Cysteine), immobilized thiol on silica (Si-Thiol), and combinations thereof.

### Claim 22 (depends on 14, 15, 16)

A method according to any one of claims 14-16, wherein the reducing agent comprises a free reducing agent, optionally wherein the free reducing agent is selected from potassium metabisulfite, sodium thioglycolate, tris(2-carboxyethyl)phosphine (TCEP), sodium thiosulfate, N-acetyl cysteine, glutathione, dithiothreitol (DTT), cystamine, dithioerythritol (DTE), dichlorodiphenyltrichloroethane (DDT), homocysteine, lipoic acid, and combinations thereof.

### Claim 23 (depends on 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

A method according to any one of claims 12-22, wherein the pH of the composition is adjusted to a pH of from about 7 to about 9.

### Claim 24 (depends on 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23)

A method according to any one of claims 12-23, wherein the temperature of the composition is adjusted to be 25° C. or less.

### Claim 25 (depends on 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

A method according to any one of claims 12-24, wherein the method inhibits the formation of one or both of N-oxides and aldehydes in the composition.

### Claim 26 (depends on 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

A method according to any one of claims 12-24, wherein the method inhibits the formation of one or both of N-oxides and aldehydes in the composition.

### Claim 27

An isolated ionizable lipid-polynucleotide adduct formed from a polynucleotide and an ionizable lipid comprising a tertiary amine group by a process comprising decomposition of the tertiary amine group of the ionizable lipid into a secondary amine or reactive aldehyde species, and interaction of the secondary amine or reactive aldehyde species with the polynucleotide.

### Claim 28

An isolated ionizable lipid-polynucleotide adduct formed from a polynucleotide and an ionizable lipid comprising a tertiary amine group, wherein the adduct is one or more selected from an adduct of an aldehyde of the ionizable lipid and the polynucleotide; an adduct of an alkyl halide of the ionizable lipid and the polynucleotide; an adduct of an anhydride of the ionizable lipid and the polynucleotide; and an adduct of an alkyl conjugated diene of the ionizable lipid and the polynucleotide.

### Claim 29

A method for detecting ionizable lipid-polynucleotide adduct in a composition comprising a polynucleotide and an ionizable lipid, wherein the ionizable lipid comprises a tertiary amine group that can decompose into a secondary amine or reactive aldehyde species capable of interacting with the polynucleotide to form ionizable lipid-polynucleotide adduct, the method comprising subjecting a sample of the composition to reverse-phase ion pair HPLC (RP IP HPLC), and optionally detecting a main peak characteristic of the polynucleotide and a late-eluting peak characteristic of the adduct.
